基于文献计量学的膀胱癌新辅助化疗分析：趋势、合作与未来方向。

BACKGROUND: Neoadjuvant chemotherapy (NAC) followed by radical cystectomy (RC) remains the cornerstone of treatment for muscle-invasive bladder cancer (MIBC). While platinum-based regimens have demonstrated benefits in tumor downstaging and improved long-term survival for selected patients, they may pose risks for those who are ineligible or unresponsive to chemotherapy. OBJECTIVE: We undertook a bibliometric analysis to elucidate the breadth of literature on NAC in bladder cancer, discern research trajectories, and underscore emerging avenues of investigation. METHODS: A systematic search of the Web of Science Core Collection (WoSCC) was conducted to identify articles pertaining to NAC in bladder cancer from 1999 to 2022. Advanced bibliometric tools, such as VOSviewer, CiteSpace, and SCImago Graphica, facilitated the examination and depicted the publication trends, geographic contributions, institutional affiliations, journal prominence, author collaborations, and salient keywords, emphasizing the top 25 citation bursts. RESULTS: Our analysis included 1836 publications spanning 1999 to 2022, indicating a growing trend in both annual publications and citations related to NAC in bladder cancer. The United States emerged as the predominant contributor in terms of publications, citations, and international collaborations. The University of Texas was the leading institution in publication output. "Urologic Oncology Seminars and Original Investigations" was the primary publishing journal, while "European Urology" boasted the highest impact factor. Shariat, Shahrokh F., and Grossman, H.B., were identified as the most prolific and co-cited authors, respectively. Keyword analysis revealed both frequency of occurrence and citation bursts, highlighting areas of concentrated study. Notably, the integration of immunochemotherapy is projected to experience substantial growth in forthcoming research. CONCLUSIONS: Our bibliometric assessment provides a panoramic view of the research milieu surrounding neoadjuvant chemotherapy for bladder cancer, encapsulating the present state, evolving trends, and potential future directions, with a particular emphasis on the promise of immunochemotherapy.

背景：新辅助化疗（NAC）后行根治性膀胱切除术（RC）仍然是肌层浸润性膀胱癌（MIBC）的治疗基石。虽然含铂方案在肿瘤降期和改善选定患者的长期生存方面显示出益处，但对于不适合或对化疗无反应的患者，它们可能存在风险。

目的：我们进行了文献计量学分析，以阐明膀胱癌 NAC 文献的广泛程度，识别研究轨迹，并强调新的研究途径。

方法：对 Web of Science 核心合集（WoSCC）进行系统搜索，以确定 1999 年至 2022 年与膀胱癌 NAC 相关的文章。先进的文献计量学工具，如 Vosviewer、CiteSpace 和 Scimago Graphica，有助于检查和描绘出版物趋势、地理贡献、机构隶属关系、期刊知名度、作者合作以及突出的关键词，强调前 25 个引文爆发。

结果：我们的分析包括 1999 年至 2022 年的 1836 篇出版物，表明膀胱癌 NAC 的年度出版物和引文数量都在增长。美国在出版物、引文和国际合作方面是主要贡献者。在发表产出方面，德克萨斯大学是领先的机构。“泌尿外科肿瘤研讨会和原始研究”是主要的出版期刊，而“欧洲泌尿学”则拥有最高的影响因子。Shariat，Shahrokh F. 和 Grossman，H.B. 分别被确定为最有成就和被引最多的作者。关键词分析揭示了出现频率和引文爆发，突出了集中研究的领域。值得注意的是，免疫化疗的整合预计将在未来的研究中大幅增长。

结论：我们的文献计量评估提供了一个关于膀胱癌新辅助化疗研究环境的全景图，包括当前状态、发展趋势和潜在的未来方向，特别强调了免疫化疗的前景。